本文選題：慢性丙型肝炎　切入點(diǎn)：高壓臭氧自體血回輸　出處：《實(shí)用肝臟病雜志》2014年03期 　論文類型：期刊論文

【摘要】：目的探討聯(lián)合高壓臭氧自體血回輸治療對(duì)干擾素治療慢性丙型肝炎(CHC)患者臨床療效和不良反應(yīng)的影響。方法 105例CHC患者被分為對(duì)照組(52例,皮下注射干擾素和口服利巴韋林)和治療組(53例,皮下注射干擾素和口服利巴韋林,聯(lián)合應(yīng)用高壓臭氧自體血回輸療法,平均10~16次),療程均為48周,隨訪24周,觀察病毒學(xué)應(yīng)答率和不良反應(yīng)發(fā)生率。結(jié)果聯(lián)合治療組患者合并血清甘油三酯、高血壓和糖尿病的發(fā)生率分別為28.3%、28.3%和28.3%,顯著高于對(duì)照組的5.8%、7.7%和7.7%(P0.05),但兩組患者在性別構(gòu)成比、平均年齡、肝功能、HCV RNA載量和肝硬化患者比率等方面差異無(wú)統(tǒng)計(jì)學(xué)意義;治療前后兩組肝功能指標(biāo)變化的差異無(wú)統(tǒng)計(jì)學(xué)意義;治療組患者發(fā)熱、流感樣癥狀和血紅蛋白減低發(fā)生率分別為50.9%、35.8%和34.0%,顯著低于對(duì)照組的73.1%、59.6%和55.8%(x2=5.5,P0.01;x2=5.9,P0.01和x2=5.0,P0.01);治療組早期病毒學(xué)應(yīng)答率、治療結(jié)束時(shí)應(yīng)答率和持續(xù)應(yīng)答率分別為83.0%、83.0%和74.4%,與對(duì)照組相比無(wú)顯著統(tǒng)計(jì)學(xué)差異(分別為88.5%、86.5%和76.3%)。結(jié)論盡管合并高代謝綜合征,干擾素聯(lián)合高壓臭氧自體血回輸治療CHC患者病毒學(xué)應(yīng)答率與對(duì)照組無(wú)顯著性差異,但顯著減少了不良反應(yīng)發(fā)生率。高壓臭氧自體血回輸治療可能成為減少干擾素不良反應(yīng)的輔助療法。
[Abstract]:Objective to investigate the effect of autotransfusion of autogenous blood combined with high pressure ozone on the clinical efficacy and adverse reactions of interferon in patients with chronic hepatitis C. methods 105 patients with CHC were divided into control group (n = 52) and control group (n = 52). 53 cases of subcutaneous injection of interferon and ribavirin were treated with subcutaneous injection of interferon and ribavirin, combined with autogenous blood transfusion of high-pressure ozone (mean 10 ~ 16 times). The course of treatment was 48 weeks and followed up for 24 weeks. Results the incidences of serum triglyceride, hypertension and diabetes in the combined treatment group were 28.33% and 28.3%, respectively, which were significantly higher than those in the control group (5.8%, 7.7% and 7.7%, P 0.05), but the sex composition ratio of the two groups was higher than that of the control group. There was no significant difference in mean age, RNA load of liver function and the ratio of patients with liver cirrhosis, there was no significant difference in the changes of liver function between the two groups before and after treatment, and there was no significant difference in the changes of liver function between the two groups before and after treatment. The incidences of influenza-like symptoms and hemoglobin reduction were 50.9% and 34.0%, respectively, which were significantly lower than those of the control group (73.1%, 59.6% and 55.8%). At the end of the treatment, the response rate and sustained response rate were 83.0% and 74.4%, respectively. There was no significant difference compared with the control group (88.5% and 76.3%, respectively). Conclusion despite the hypermetabolic syndrome, there was no significant difference between the two groups. The virological response rate of patients with CHC treated with interferon combined with high-pressure ozone autologous blood transfusion was not significantly different from that of the control group. However, the incidence of adverse reactions was significantly reduced. Autotransfusion of high pressure ozone may be an adjuvant therapy to reduce adverse reactions of interferon.
【作者單位】： 新疆醫(yī)科大學(xué)第一附屬醫(yī)院肝病科;
【基金】：新疆維吾爾自治區(qū)科技支撐項(xiàng)目(編號(hào):201141137) 國(guó)家自然科學(xué)基金資助項(xiàng)目(編號(hào):81360138)
【分類號(hào)】：R512.63

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 阿米娜·依明;鐵木爾·玉努斯;麗娜;;聚乙二醇干擾素α-2a和利巴韋林聯(lián)合治療慢性丙型肝炎臨床觀察[J];實(shí)用肝臟病雜志;2011年06期

2 李杰;陳杰;莊輝;;丙型肝炎的流行病學(xué)[J];實(shí)用肝臟病雜志;2012年05期

3 賈繼東;2004年丙型肝炎防治方案要點(diǎn)(治療部分)解讀[J];臨床肝膽病雜志;2004年04期

4 霍荻;楊運(yùn)高;敖飛健;戴煒;李莉潔;郭亞兵;;醫(yī)用三氧與中藥對(duì)醋氨酚犬中毒性肝炎的保護(hù)作用[J];世界華人消化雜志;2007年03期

5 黃長(zhǎng)形;白雪帆;;慢性丙型病毒性肝炎抗病毒治療的不良反應(yīng)及其處理[J];中華傳染病雜志;2006年03期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳秋林;;丙型肝炎患者干擾素抗病毒治療中不良反應(yīng)的觀察與護(hù)理[J];當(dāng)代護(hù)士(專科版);2010年10期

2 寧洪葉;彭福江;周福元;楊玲;彭R，

本文編號(hào)：1583602